Folfirnox to Treat Pancreatic Cancer | Pancreatic Cancer North America

Pancreatic Cancer Canada is becoming Pancreatic Cancer North America, uniting across borders to make pancreatic cancer a survivable disease.

I Need Support

About Pancreatic Cancer

Signs and Symptoms Risk Factors Treatment Options

Patients & Caregivers

Programs Resources Treatment Centres Genetic Testing Clinical Trials Palliative Care

Accelerating Research

I Want to Help

Ways to Give

Get Involved

Start a Fundraiser
Pancreatic Cancer Awareness Month

About Us

Impact Reports

1.888.726.2269

[email protected]

316-4211 Yonge St. Toronto, ON M2P 2A9

Charitable Registration Number 84870 1967 RR0001

—Take Action — Donate Today — Survival, Not Sympathy — Take Action - Donate Today - Survival, Not Sympathy

1.888.726.2269

[email protected]

316-4211 Yonge St. Toronto, ON M2P 2A9

Charitable Registration Number 84870 1967 RR0001

—Take Action — Donate Today — Survival, Not Sympathy — Take Action - Donate Today - Survival, Not Sympathy

—Take Action — Donate Today — Survival, Not Sympathy — Take Action - Donate Today - Survival, Not Sympathy

Back to newsroom

News

Folfirnox to Treat Pancreatic Cancer

June 9, 2019

Pancreatic cancer treatment doctor, Dr. Jim Biagi recommends the approval of Folfirinox for the treatment of pancreatic cancer in light of its recent success rates.

Be part of the force driving answers for this devastating disease.

Make a donation towards pancreatic cancer research and support programs.

Keep in the loop:

Read more PCNA News:

discover more

May 13, 2026

Research

Pancreatic Cancer North America launches access to free genomic testing with OncoHelix to support treatment decisions for patients across Canada

June 13, 2025

Research

Research Update – NeoPancONE Study Results Presented at ASCO 2025

June 26, 2025

Research

Our Impact in 2024: A New Era